Gain-of-function mutations in iRHOM2 underlie Tylosis with oesophageal cancer (TOC), characterized by palmoplantar thickening, upregulate K16 with robust downregulation of its type II keratin binding partner, K6. Here, RHBDF2 is linked to palmoplantar keratoderma-esophageal carcinoma syndrome.